blood analysis graphic

MEDITECH Customers Offer Convalescent Plasma Therapy

The FDA recently allowed health systems to begin using CP therapy to treat patients, and several MEDITECH customers have launched their own CP initiatives.

 | 

As we continue to wait for therapeutic agents or vaccines for COVID-19, enough time has passed for the first wave of recovered patients to become viable donors for convalescent plasma (CP) therapy. The FDA recently allowed health systems to begin using CP therapy to treat patients, and several MEDITECH customers have launched their own CP initiatives:

  • Valley Hospital in New Jersey treated its first patients with CP therapy in April. Dr. Neil Gaffin, Valley’s infectious disease specialist, discussed the process in a televised segment on WABC in New Jersey.
  • Avera Health has not only been reaching out to recovered COVID-19 patients for donations, but also brought together staff from a variety of areas - from bone marrow transplant coordinators to its research - to help make CP therapy available.
  • Residents in Berkshire, MA began donating blood through the Albany Medical Center, and Berkshire Health Systems has also launched its own program to collect blood from recovering patients.

Stay up-to-date on how MEDITECH customers are supporting their patients, staff, and communities as they combat the COVID-19 pandemic. Also, for customers who want to review our latest Guidance Documents, they can be accessed on our Client Services COVID-19 Resource page.